Serum Institute of India, the world’s largest vaccine producer by volume, is close
to signing a
supply contract with the country’s Central government and
to fix prices at Rs 250 ($3.39) per dose of the vaccine, Business Standard reported on Tuesday, citing people familiar with the matter.
The government is pinning its hopes for mass
Serum Institute, which lodged the first formal application for emergency-use approval of AstraZeneca’s shot on Monday.
Chief Executive Officer Adar Poonawalla had earlier said the vaccine would be priced at Rs 1,000 ($13.55) per dose in India’s private market, but governments signing large
supply deals would
likely buy it at lower prices.
Poonawalla had said
Serum will first focus on supplying the vaccine
to Indians before distributing it
to other countries.
With 9.70 million COVID-19 cases recorded so far, India is second only
to the United States and is accelerating its review of vaccines developed by Pfizer Inc and AstraZeneca
to authorize for emergency use, a senior official said on Monday.
The state-run Indian Council of Medical Research,
Serum Institute and the Indian Ministry of Health did not immediately respond
to Reuters request for comments.